There are two types of thyroid tumours: those that develop from parafollicular cells and those that develop from follicular cells (C cells). Papillary carcinoma, follicular carcinoma, oncocytic cell carcinoma (Hürthle), weakly differentiated carcinoma, and anaplastic carcinoma are examples of differentiated thyroid cancer, which develops from follicular cells. By the year 2022, it is anticipated that there will be 43,800 instances of thyroid cancer in the United States of America, since the incidence has been steadily rising. The majority of instances of this neoplasm, which is classified as the most frequent endocrine tumour and accounts for about 3 percent of all malignant tumours in humans, occur in women in 75 percent of cases, and in people under 55 in 60 percent of cases. The conventional one-size-fits-all strategy to differentiated thyroid cancer has to be reevaluated in light of the rise in the prevalence and incidence of low-risk thyroid cancer during the past 10 to 20 years. This shift to a more customised approach to treating thyroid cancer patients has produced a diagnosis, initial treatment, adjuvant therapy, and follow-up strategy for patients with differentiated thyroid cancer that is considerably more risk-adapted. In this research, evidence-based medicine is used to review current knowledge regarding the clinical presentation, diagnostic process, and treatment of thyroid cancer.
Author (s) Details
Fernando Cordera
Sociedad Quirúrgica S.C., American British
Cowdray Medical Center, Mexico City, Mexico.
Rodrigo Arrangoiz
Mount Sinai Medical Center, Columbia
University, Miami, FL, USA.
View Book :- https://stm.bookpi.org/CPMS-V6/article/view/7688
No comments:
Post a Comment